Dow Jones 30 Stocks SEC Filings — October 21, 2026

Fiscal Q3 2026 sales grew 5.9% YoY to $25,399M and nine-month sales rose 7.4% to $74,771M, showing underlying top-line momentum

Q3 net earnings fell to $210M (0.8% of sales) from $5,152M and nine-month net earnings fell 49.4% to $10,979M, with diluted EPS of $4.49 vs $8.94, driven by a $5,780M other expense swing

Gross margin compressed 150 bps to 68.1% and R&D rose 26.7% in the quarter, indicating operating cost pressure outpacing sales growth

Cash and equivalents declined to $16,910M from $19,709M at year-end 2025, a reduction of about $2.8B over the period that constrains flexibility for buybacks or M&A

Q3 effective tax benefit of $(176)M on pre-tax earnings of $34M, versus a 31.2% provision a year earlier, inflating the relative quality of the reported near-zero margin and warranting scrutiny of the tax line

Chief Legal Officer Pate R. Hewitt sold about 43,100 shares (~$9.8M gross) across six transactions, largely after exercising options at $132.69, which is a planned disposition under a Rule 10b5-1 plan rather than an open-market conviction purchase

Hewitt retained 8,791 shares after the transactions, meaning the executive kept a residual stake despite substantial exercise-and-sell activity, a mildly neutral-to-positive alignment signal

Nine-month diluted EPS of $4.49 versus $8.94 implies roughly half of prior-year earnings power, making normalized-earnings valuation the key analytical question

Other expense of $5,780M in Q3 versus $(478)M income a year earlier is the primary driver of the net earnings collapse; the composition is not disclosed in the summary and must be verified in the MD&A

Q3 in-process R&D impairments of $339M and restructuring charges of $181M (vs $63M a year earlier) signal pipeline write-downs and cost actions that could recur

Gross margin fell 150 bps to 68.1% while R&D rose 26.7%, eroding operating leverage at a point when sales growth is only mid-single digit

Cash and equivalents dropped about $2.8B from year-end 2025 to $16,910M, a trend to monitor given the scale of the charges and potential cash-intensive restructuring

The effective tax benefit of $(176)M on $34M pre-tax earnings is anomalous and may not persist, so reported quarterly earnings quality is weak

The Chief Legal Officer sold roughly $9.8M of stock in the period, with the summary tagged negative sentiment and materiality 8/10, which may be read by some investors as a negative signal even though it is plan-based

Sales growth of 5.9% (Q3) and 7.4% (nine-month) suggests the underlying franchise is intact; if the $5,780M other expense is non-recurring, normalized earnings could be materially higher than reported

If in-process R&D impairments and restructuring charges prove one-time, the cost base could normalize, supporting margin recovery from the current 68.1% gross margin level

With nine-month diluted EPS of $4.49 versus $8.94 prior year, the stock may price in a durable earnings decline; a verified non-recurring classification could create a re-rating opportunity

Hewitt retained 8,791 shares after exercising and selling, indicating continued equity exposure rather than full exit, supportive of alignment even as the sale headline appears negative

The unusual $(176)M tax benefit suggests a potential reversal to a more typical provision; if pre-tax earnings recover, the lower tax burden could amplify EPS recovery

J&J shows mid-single-digit sales growth (5.9% Q3, 7.4% nine-month) alongside a 49.4% nine-month net earnings decline, a pattern where non-operating and one-time charges dominate bottom-line outcomes despite steady top-line expansion

The $5,780M other expense and $339M IPR&D impairments show large-cap healthcare reporting increasingly influenced by acquisition-related and pipeline write-downs, complicating comparison of reported earnings across periods

Chevron's Chief Legal Officer executing option exercises and sales under a 10b5-1 plan reflects routine liquidity management by senior executives, which should be weighed against retained holdings rather than read as a directional call

Review the 10-Q MD&A to identify what drives the $5,780M other expense line and whether it is recurring; this is the single most important data point for valuation [Filing date 2026-10-21]

Monitor for further restructuring or pipeline write-downs in subsequent quarters, given the $181M restructuring and $339M impairment in Q3 [Next quarterly report]

Track whether cash continues declining from $16,910M, particularly if restructuring or M&A payments accelerate [Next quarterly report]

Watch whether the 68.1% gross margin stabilizes or continues compressing against rising R&D spend [Next quarterly report]

Monitor further Form 4 filings to confirm whether the executive continues to sell under the 10b5-1 plan or retains the residual 8,791-share position [Ongoing Form 4 filings]

Watch whether the effective tax rate reverts from the $(176)M benefit toward a normalized provision as pre-tax earnings recover [Next quarterly report]